Mr. Andre Larente reports

DIAGNOS ANNOUNCES GRANT OF STOCK OPTIONS

Diagnos Inc. has granted 250,000 stock options to one of its directors, Michael Braeuel, in connection with his appointment to the corporation's board of directors announced by way of news release on Feb. 29, 2024.

Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The exercise price of the stock options has been established at 28 cents per common share. The date of the grant is March 4, 2024. The expiry date to which the stock options can be exercised is March 4, 2029.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.